How Using apoB Can Improve Your Care
Starts On:
01/01/2023: 12:00 AM
Ends On:
12/31/2024: 11:45 PM
Type:
Online Course
Credits:
1
Description:
All individuals in control of content report no relevant financial relationship.
Dr. Sniderman began and has continued a series of studies, which identified the commonest dyslipoproteinemia associated with coronary artery disease- hyperTg hyperapoB. Study of the pathophysiology of hyperTg hyperapB led to studies of the regulation of hepatic apoB secretion and the uptake and release of fatty acids by adipose tissue. He has conducted an extensive series of epidemiological studies, which have demonstrated apoB to be superior to LDL-cholesterol as a marker of the risk of vascular disease. His current research interests are to understand he regulation of plasma LDL, to create simplified but advanced diagnostic algorithms to recognize and reat those with and those at high risk of vascular disease, and to develop new models to determine the absolute value of different strategies to identify and treat those at risk of vascular disease.
Join Dr. Elkin Nunez as he moderates a discussion with a multidisciplinary team of AMG clinicians for an essential clinical update about diabetes management, current guidelines and new therapies and treatments in the ambulatory setting.
Dr. Sniderman began and has continued a series of studies, which identified the commonest dyslipoproteinemia associated with coronary artery disease- hyperTg hyperapoB. Study of the pathophysiology of hyperTg hyperapB led to studies of the regulation of hepatic apoB secretion and the uptake and release of fatty acids by adipose tissue. He has conducted an extensive series of epidemiological studies, which have demonstrated apoB to be superior to LDL-cholesterol as a marker of the risk of vascular disease. His current research interests are to understand he regulation of plasma LDL, to create simplified but advanced diagnostic algorithms to recognize and reat those with and those at high risk of vascular disease, and to develop new models to determine the absolute value of different strategies to identify and treat those at risk of vascular disease.
Join Dr. Elkin Nunez as he moderates a discussion with a multidisciplinary team of AMG clinicians for an essential clinical update about diabetes management, current guidelines and new therapies and treatments in the ambulatory setting.
Objectives:
After participation, the learner should be able to:
1. Describe apoB and what it tells you that TC, LDL-C, non-HDL-C and TG do not?
2. Describe discordance analysis and how it demonstrates that apoB is a more accurate marker of cardiovascular risk and the adequacy of lipid-lowering therapy than LDL-C or non-HDL-C?
3. Recognize examples of how without apoB, accurate diagnosis and therapy is not possible.
4. Describe how apoB can clarify, simplify, and amplify your ability to diminish cardiovascular risk due to the atherogenic lipoproteins.
1. Describe apoB and what it tells you that TC, LDL-C, non-HDL-C and TG do not?
2. Describe discordance analysis and how it demonstrates that apoB is a more accurate marker of cardiovascular risk and the adequacy of lipid-lowering therapy than LDL-C or non-HDL-C?
3. Recognize examples of how without apoB, accurate diagnosis and therapy is not possible.
4. Describe how apoB can clarify, simplify, and amplify your ability to diminish cardiovascular risk due to the atherogenic lipoproteins.